Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis

Global Chronic Obstructive Pulmonary Disease (COPD) Market To Reach USD 33.19 Billion By 2033 At A CAGR Of 4.4% FMI

(MENAFN- EIN Presswire)

Chronic Obstructive Pulmonary Disease (COPD) Market

COPD market grows with rising disease prevalence, innovation in therapies, and increasing global healthcare investments.

COPD drugs market in the region. Asia Pacific is expected to hold the highest CAGR of 4.2% during the forecast period." - Sabyasachi Ghosh, Principal Consultant. Future Market InsightsNEWARK, DE, UNITED STATES, April 28, 2025 /EINPresswire / -- The global chronic obstructive pulmonary disease market is poised for substantial growth, with projections indicating a valuation of USD 21.58 billion in 2023. Driven by increasing alcohol consumption, tobacco use, and rapid urbanization, the demand for COPD-related therapies and products is expected to surge at a compound annual growth rate (CAGR) of 4.4% between 2023 and 2033. By the end of the forecast period, the market is projected to total around USD 33.19 billion.

According to the Global Burden of Disease study conducted by the Institute of Health Metrics and Evaluation in 2016, there were approximately 251 million cases of COPD worldwide. The World Health Organization (WHO) further reported that around 200 million individuals globally were diagnosed with COPD in 2016. This high prevalence underscores the growing burden of the disease and the urgent need for effective management solutions.

Track the Latest Market Developments: Request a Sample Report! #5245502d47422d3136323135

Urbanization and Lifestyle Factors Driving Disease Prevalence

The risk of developing COPD is exacerbated by rapid urbanization, particularly in emerging economies across the Asia Pacific region. Increased exposure to environmental pollutants, lung irritants, and industrial emissions is contributing significantly to the rising incidence of the disease. Furthermore, WHO emphasizes that exposure to tobacco smoke-both first-hand and second-hand-remains the most significant risk factor for COPD worldwide.

The increasing adoption of smoking habits among millennials, paired with a surge in alcohol consumption, has further intensified the demand for COPD treatments. At the same time, growing awareness about the availability and effectiveness of generic medications is expected to support market expansion, making treatments more accessible and affordable for a broader segment of the population.

Economic Burden Highlighting the Need for Solutions

The economic impact of COPD is substantial and growing. According to the Centers for Disease Control and Prevention (CDC), the financial burden related to COPD in the United States was USD 32.1 billion in 2010, escalating to USD 49 billion by 2020. This continual rise in healthcare costs highlights the urgent need for innovative and cost-effective therapeutic solutions, thereby presenting significant growth opportunities for companies operating in the COPD market.

Key Takeaways

. North America Leads the COPD Market:North America is expected to dominate the global COPD market with a 44% share in 2023, driven by a structured healthcare industry, strong reimbursement policies, ongoing R&D activities, rising smoking rates, and increasing air pollution.

. Asia Pacific Emerges as a Lucrative Market:Asia Pacific is projected to hold the second-highest market share at 43% in 2023, fueled by a growing geriatric population, high disease incidence, and urbanization-induced air pollution, positioning the region for strong future growth.

. Combination Therapy to Stay Ahead:The combination therapy segment leads the COPD market by drug class, accounting for 45% share and expected to grow at a CAGR of 4.3%, owing to higher treatment efficacy and increasing regulatory approvals.

. Chronic Bronchitis Dominates by Type:Chronic bronchitis is the leading type within the COPD market, holding a 43% share in 2022 and expected to expand at a CAGR of 4.2%, largely due to rising prevalence among smokers and growing cases of airflow blockage.

. Retail Pharmacies Drive Distribution Growth:Retail pharmacies captured 42% of the COPD market by distribution channel in 2022, with anticipated growth of 4.2% CAGR, supported by the expanding number of retail pharmacies and increased therapeutic dispensing.

Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!

Competitive Landscape

The global COPD market is characterized by intense competition, with key players focusing on product innovation, strategic partnerships, and expanding their geographic footprint. Some of the leading players in the market include:

. Almirall. AstraZeneca. Boehringer Ingelheim International GmbH. CHIESI Farmaceutici S.P.A.. F. Hoffmann-La Roche Ltd.. GlaxoSmithKline plc.. Kyowa Hakko Kirin. Mylan N.V.. Novartis AG. Orion Corporation. Sanofi. Sunovion Pharmaceuticals, Inc. (a Sumitomo Dainippon Pharma Co., Ltd. Company). Teva Pharmaceutical Industries Ltd.. Theravance Biopharma. Verona Pharmaceuticals

Recent Strategic Developments

Innovation and clinical advancements remain at the forefront of the COPD market:

. In June 2022, Verona Pharma announced the completion of patient enrollment for its pivotal ENHANCE-1 trial, involving more than 800 subjects. The study aims to evaluate the efficacy of ensifentrine for the maintenance treatment of COPD. The company anticipates releasing top-line data for ENHANCE-1 by the end of 2022, with further insights from ENHANCE-2 expected in the third quarter of the year.

. In May 2022, Alembic Pharmaceuticals Ltd secured final approval from the U.S. Food & Drug Administration (USFDA) for its generic version of Arformoterol Tartrate inhalation solution, intended for the long-term treatment of bronchoconstriction in COPD patients. The approval covers a strength of 15 mcg (base)/2 mL unit-dose vial, adding a cost-effective therapeutic option to the U.S. Market.

Segmentation Overview

The Chronic Obstructive Pulmonary Disease (COPD) market is segmented as follows:

. By Drug Class:o Combination Therapyo Bronchodilatorso Corticosteroidso Phosphodiesterase Type 4 Inhibitorso Mucokineticso Others

. By Type:o Chronic Bronchitiso Emphysema

. By Distribution Channel:o Hospital Pharmacieso Retail Pharmacieso Online Pharmacies

. By Region:o North Americao Europeo Asia Pacifico Latin Americao Middle East & Africa

Looking Ahead

The future of the COPD market looks promising as healthcare systems worldwide are increasingly focusing on early diagnosis, innovative treatment approaches, and public awareness campaigns to manage and mitigate the disease. With continued research, partnerships, and government support, the COPD market is expected to offer significant opportunities for both new entrants and established players over the next decade.

As COPD continues to pose a major global health challenge, the importance of innovation, affordability, and accessibility in treatment solutions will be paramount. Stakeholders investing in next-generation therapies, respiratory support devices, and comprehensive disease management programs are poised to make a significant impact in improving patient outcomes and capturing a larger share of the growing market.

Ankush NikamFuture Market Insights, Inc.+91 90966 84197email us hereVisit us on social media:LinkedInFacebookYouTubeX

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MENAFN28042025003118003196ID1109479144

Climate Change: Adverse Impacts On COPD Detailed In GOLD Review

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with chronic obstructive pulmonary disease (COPD), according to a report published in the American Journal of Respiratory and Critical Care Medicine.

The report, written by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee, cited 140 research articles detailing the effects of climate change on human health as well as the likely future effects of climate change on people with COPD.

Climate change has led to an increase in the frequency and intensity of extreme weather events, which have affected overall global mortality and morbidity, according to the GOLD Science Committee report. Since the 1990s, each successive decade has been warmer than previous decades. An increase in deaths has occurred in the general population during heatwaves, and climate change also is associated with worsening of air pollution and has led to longer wildfire seasons.

Research has shown that patients with COPD have an increased risk of mortality from exposure to heat and cold. In extreme weather, respiratory and cardiovascular events are the most common causes of mortality in patients with COPD. Heat and cold also are associated with a higher risk for hospitalization in patients with COPD.

"

Climate change had significant impacts on people with COPD…. Future increases in the number, duration, and severity of periods with extreme heat and cold as well as secondary changes in the frequency and intensity of wildfires, dust storms, aeroallergens, and outdoor air pollution…will worsen the current situation.

Evidence has shown a link between air pollution and increased symptoms and exacerbation rates in patients with COPD, as well as an increased risk of death. Although some research has shown synergistic effects between heat and air pollution exposure on all-cause mortality, respiratory mortality, and hospital admissions in general populations, other studies have found no interaction.

Most research has focused on the effect of outdoor air temperature on mortality and morbidity in COPD. Conflicting evidence has been found on the interactive effects of outdoor heat and pollution on respiratory outcomes. Some research has shown a greater pollutant effect on COPD hospital admissions and emergency visits during low temperatures or winter.

Studies at an individual patient level regarding the relationship of temperature, symptoms, and lung function in COPD have found that higher outdoor temperatures are associated with increased dyspnea, especially during days patients go outside. Susceptibility to exacerbations, lower respiratory reserve, and cardiac comorbidity among patients with COPD make them vulnerable to extreme cold and heat and higher concentrations of pollutants, dust, fungi, and aeroallergens that occur with climate change.

Some medications taken by patients with COPD may increase their vulnerability to temperature. Patients who have a lower socioeconomic status, those living in inner cities, the elderly, and those in more temperate climates may have limited or no access to air conditioning or heating.

Management recommendations in patients with COPD exposed to the effects of climate change are similar to those for the general population and are based on common sense rather than evidence based, the GOLD committee noted.

Patients with COPD in temperate and colder climates are advised to keep bedroom temperatures high enough to counter the harmful health effects of cold, with 18°C (64.4°F) considered the threshold for better health status. For heatwaves and high temperature periods, patients with COPD should stay adequately hydrated, take their medications as prescribed, stay out of the heat, and keep living spaces less than 32°C (89.6°F) and sleeping spaces less than 24°C (75.2°F). They should also protect themselves against smoke and ash during and after wildfires.

"Climate change had significant impacts on people with COPD," and environmental changes may alter "the prevalence and geographical distribution of COPD," the review authors noted. "Future increases in the number, duration, and severity of periods with extreme heat and cold as well as secondary changes in the frequency and intensity of wildfires, dust storms, aeroallergens, and outdoor air pollution, particularly ground-level ozone, will worsen the current situation," the report stated. "People with COPD must be made aware of the potential effects of these events and advised how to minimize their impact."

British Lung Foundation Launches Patient Passport For World COPD Day

On World COPD Day, taking place on 19 November, every GP surgery in the UK will receive the first nationally available COPD Patient Passport, aimed at ensuring chronic obstructive pulmonary disease (COPD) patients are getting the best care.

The passport has been developed by the British Lung Foundation (BLF) in partnership with the Primary Care Respiratory Society UK (PCRS-UK).

An interactive online version of the Patient Passport is also available, and can be used by patients to generate a printable personalised report, to use in discussion with their healthcare professional. The passport forms part of this year's World COPD Day theme, 'Living with COPD', which encourages people affected by COPD to take control of the disease and live fuller, more active lives.

In addition, at 8pm on World COPD Day, the BLF and the Association of Respiratory Nurse Specialists will host a COPD Twitter chat for health care professionals and patients. It will cover issues such as early diagnosis and patient self-management. People can join the Twitter chat and ask questions via the hashtag #LiveCOPD.

COPD incorporates the conditions previously known as emphysema and chronic bronchitis. It kills around 30,000 a year in the UK – more than any type of cancer other than lung cancer – and can severely affect quality of life. However, of the estimated three million people living with COPD in this country, over two million remain undiagnosed without the support and treatment needed to help them manage the condition.

A COPD patient passport created by North West Respiratory clinical leads, respiratory specialists and patients was the inspiration for the BLF COPD Patient Passport.

Dr Noel Baxter, GP and medical adviser at the BLF, said: "Self-management has become increasingly crucial in a patient's pathway. It can help reduce exacerbations and the number of COPD patients being admitted and readmitted to hospital.

"This new COPD Patient Passport will prove to be an invaluable tool for health care professionals to use with their COPD patients. It will help ensure patients are managing their condition as effectively as possible as well as receiving coordinated care. This could be as simple as referring them on to a local Breathe Easy support group or talking through their self-management plan."

Symptoms of COPD include breathlessness, a persistent cough, excess mucus production and wheezing. It accounts for around 1.4 million GP consultations a year, and is the second most common cause of emergency hospital admissions in England. It has been estimated that a proactive approach to COPD care pathway management could save the NHS around £800m over 10 years. One in five people in the UK is affected by lung disease.

World COPD Day is organised by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in collaboration with health care professionals and COPD patient groups throughout the world. The first one was held in 2002.

Link

AstraZeneca completes takeover of Almirall respiratory franchise

---